Latest News
See all →ITM Presents Dosimetry Data from Phase 3 COMPETE Trial Supporting Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors at EANM 2025 Annual Congress
- Study showed targeted tumor uptake with low healthy organ exposure in broad cohort of 207 patients
- Supports therapeutic potential of ITM’s proprietary…
ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161
Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical…
Read moreITM to Present COMPETE Dosimetry Data and Host Satellite Symposium at EANM 2025
Garching / Munich, Germany, September 16, 2025 -ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today…
Read more
